** Shares of Paradigm Biopharmaceuticals PAR.AX fall as much as 25.9% to A$0.430, their lowest levels since Nov 26
** The drug development firm announces A$16 mln ($10.23 mln) placement to institutional and sophisticated investors
** Issue price of A$0.40 represents a discount of 31% to last close on Dec 4 when trading was halted pending capital raising announcement
** Funds to support global Phase III trials for osteoarthritis treatment with iPPS, beginning in Australia and expanding to key U.S. sites
** Objective of Phase III trials include demonstration of improvement in pain and function with subcutaneous injections of pentosan polysulfate sodium (iPPS)
** Stock has risen 27.1%, YTD
($1 = 1.5642 Australian dollars)
(Reporting by Namrata Verma in Bengaluru)
((namrata.verma@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。